Ophthalmic Company GrayBug to Present at BIO CEO & Investor Conference on February 8

Baltimore, MD – February 4, 2016 – GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, announced that Jeffrey L. Cleland, PhD, GrayBug Interim Chief Executive Officer, will present an update of the company’s progress on Monday, February 8 at 2:45 pm, during the 18th Annual BIO CEO & Investor Conference in New York City.

The company recently completed a 6 month study in animals for its lead program, GB-102, a therapy for twice-yearly treatment of wet AMD.  This preclinical study demonstrated the ability of GrayBug’s proprietary technology to deliver its small molecule drug that blocks both VEGF and PDGF for over 6 months after a single intravitreal injection in rabbits.  The technology achieves the 6 month release profile without inflammation or toxicity after an intravitreal injection – an unprecedented result for a non-steroid drug delivered to the eye.  The FDA has agreed with the company’s plans for GB-102 IND-enabling studies and for a Phase 1/2 study in wet AMD patients to be initiated at the end of 2016 to confirm the results to date in animals.

Date: Monday, February 8th
Time: 2:45 PM
Location: Waldorf Astoria New York
Room: Park North
Track: Ophthamology

About GrayBug, Inc.

GrayBug is developing injectable controlled release technologies to reduce the frequency of ocular therapy to twice per year. The feasibility of this technology has been validated in animals with the company’s lead program, GB-102, a therapy targeting VEGF and PDGF pathways. GB- 102 has the potential for treating patients with neovascular (wet) AMD just twice a year, compared to 12-15 times a year with the currently available drugs. These technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products and are also being developed for twice per year treatment of glaucoma.

GrayBug was founded as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. GrayBug’s technologies were co-developed by GrayBug founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with GrayBug cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD. The technologies were exclusively licensed from Johns Hopkins University. For more information, please visit www.graybug.com.

Related News

Press release

Joint Statement on Retina Clinical Trials and COVID-19

To our Colleagues in the Retina Clinical Trials Community: We all take the health and safety of patients, healthcare providers, and our local communities very seriously, and the ongoing pandemic is challenging healthcare delivery and Read more…

Press release

Graybug Vision Concludes Patient Enrollment in its Phase 2b Clinical Trial of GB-102 in Wet Age-Related Macular Degeneration and Accelerates Trial Read-out by Approximately Six Months

REDWOOD CITY, Calif., March 18, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today announced the early closing of Read more…

Press release

Graybug Vision presents preclinical results for GB-401, a potential sustained-delivery treatment of up to six months for primary open angle glaucoma, at the American Glaucoma Society Annual Meeting

REDWOOD CITY, Calif., February 28, 2020 – Graybug Vision, Inc., a biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve, today presented pre-clinical study results for GB-401, a novel injectable Read more…